Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Total Non-Current Liabilities of $878.0 million for Q1 2026, down 15.09% year-over-year from $1.0 billion in Q1 2025, and down 12.55% quarter-over-quarter from $1.0 billion in Q4 2025.
Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Arcus Biosciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $878.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 15.09% year-over-year to $878.0 million; the TTM figure through Mar 2026 stood at $878.0 million (down 15.09% YoY), while the FY2025 annual figure was $1.0 billion, up 1.11% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $878.0 million, down from $1.0 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.2 billion in Q3 2024, with the low at $679.0 million in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $1.0 billion (2025), against an average of $970.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 181.77% in 2022, then slipped 29.38% in 2025.
- Arcus Biosciences' Total Non-Current Liabilities stood at $1.2 billion in 2022, then fell by 17.84% to $953.0 million in 2023, then grew by 4.2% to $993.0 million in 2024, then increased by 1.11% to $1.0 billion in 2025, then retreated by 12.55% to $878.0 million in 2026.
- Business Quant data shows RCUS's Total Non-Current Liabilities at $878.0 million in Q1 2026, $1.0 billion in Q4 2025, and $822.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 800.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 800.00 Mn |
| Mar 31, 2026 | 878.00 Mn |
| Dec 31, 2025 | 1.00 Bn |
| Sep 30, 2025 | 822.00 Mn |
| Jun 30, 2025 | 916.00 Mn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 993.00 Mn |
| Sep 30, 2024 | 1.16 Bn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 1.16 Bn |
| Dec 31, 2023 | 953.00 Mn |
| Sep 30, 2023 | 1.05 Bn |
| Jun 30, 2023 | 1.08 Bn |
| Mar 31, 2023 | 1.11 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 678.96 Mn |
| Jun 30, 2022 | 714.71 Mn |
| Mar 31, 2022 | 732.97 Mn |
| Dec 31, 2021 | 628.45 Mn |
| Sep 30, 2021 | 286.48 Mn |